http://www.acc.org/Feed?clinicalTopicID=58616d42-1fda-49eb-a3ed-40ba0d5d99c0 Clinical Topic Feed: Chronic Angina en /Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/ORBITA-Analysis Patients with lower microvascular resistance (MVR) saw greater placebo-controlled benefit from PCI, according to a retrospective analysis of the ORBITA trial published April 29 in JACC: Cardiovascular Interventions. 1778087340000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-830am-orbita-cto-acc-2026 In patients with symptomatic single-vessel coronary chronic total occlusion (CTO), PCI for CTO improved angina beyond placebo, according to findings from the ORBITA-CTO trial presented at ACC.26 and simultaneously published in JACC. 1774791000000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-stemidtu-acc-2026 Compared with immediate PCI alone, the combination of mechanical left ventricular (LV) unloading using a transvalvular micro-axial flow pump (TV-mAFP) plus delayed PCI did not reduce infarct size in patients with anterior STEMI without cardiogenic shock, according to findings from the STEMI-DTU trial presented at ACC.26 and simultaneously published in JACC. 1774708320000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/19/17/12/Dobermann Two brief reports in JACC on the DOBERMANN-T and DOBERMANN-D trials found that among patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), early interleukin 6 (IL 6) receptor inhibition with tocilizumab safely reduced systemic inflammation but showed inconclusive effects on NT proBNP. In contrast, early dobutamine infusion did not lower NT proBNP levels but did reduce systolic blood pressure (SBP) without raising safety concerns. 1773942840000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/16/16/27/Pre-Hospital-Glycoprotein-IIb-IIIa-Inhibition-With-Zalunfiban-in-STEMI The CELEBRATE (CeleCor Blinded Randomized Trial in ST-Elevation Myocardial Infarction) trial was a phase 3, multicenter, double-blind, placebo-controlled study that evaluated the efficacy and safety of a single subcutaneous injection of zalunfiban (CeleCor Therapeutics), a novel glycoprotein IIb/IIIa inhibitor... 1773751800000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1772370600000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/25/19/29/NSTEMI-Algorithm Both the European Society of Cardiology 0/1-hour algorithm (ESC 0/1h-algorithm) and the high-sensitivity troponin in the evaluation of patients with acute coronary syndrome 0/2-hour or 0/3-hour pathway (High-STEACS 0/2h-0/3h-pathway) demonstrated "comparable and excellent performance" in diagnosing patients presenting with acute chest discomfort, according to a prospective, multicenter study published in JACC. 1772051220000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/11/18/58/Substantial-Hospital-Level-Variation-in-Immediate-Coronary-Angiography-Among-Patients-With-STEMI-and-OHCA-NCDR-Study Among patients presenting with both out-of-hospital cardiac arrest (OHCA) and STEMI, substantial hospital-level variation was found in providing immediate coronary angiography (CA), according to a Brief Report published Feb. 11 in JACC. 1770836700000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/03/17/39/eagles-eye-view-04feb2025 In this week’s View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. 1770217200000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/02/20/04/ADDICT-ICCU Recreational drug use is a strong, independent predictor of worse one-year cardiovascular outcomes in patients with acute coronary syndrome (ACS), significantly in those with STEMI, according to results from the ADDICT-ICCU study published Jan. 23 in JACC: Advances. 1770062700000 Articles and Stories